B of A Securities Downgrades Biohaven Ltd. to 'Sell'
B of A Securities cuts Biohaven Ltd. to 'sell' with a $11 target, a 26.08% downside from the current price.
Key Points
- B of A Securities downgraded Biohaven Ltd. (NYSE:BHVN) to a 'sell' on June 29, 2026, setting a new price target of $11.
- B of A Securities's $11 price target implies 26.08% downside from Biohaven Ltd.'s ($BHVN) current $14.88 share price.
- Shares of Biohaven Ltd. traded near $15.83 on Monday, with a market cap of about $2.38 billion and a forward P/E ratio showing no meaningful value due to lack of profitability.
- Insiders at Biohaven Ltd. made notable purchases in April 2026, while other analysts maintain a 'buy' consensus with a mean target price of $22.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
B of A Securities has downgraded Biohaven Ltd. (NYSE:BHVN) to a 'sell' rating, setting a new price target of $11. This change was announced on June 29, 2026, by analyst Jason Gerberry. The previous target was not specified. Shares of Biohaven traded near $15.83 on Monday.
B of A Securities vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Biohaven Ltd. Stock Down 3.4%
Shares of NYSE:BHVN traded around $15.83 on Monday. Biohaven Ltd. has a market cap of approximately $2.38 billion. The company does not have a meaningful P/E ratio due to its lack of profitability, with an EPS of -$5.57. The stock has a beta of 3.306, indicating higher volatility compared to the market. Over the past year, shares have ranged from a low of $7.48 to a high of $18.57. The 50-day moving average is $10.82, while the 200-day moving average is $11.56.
$BHVN price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Other Institutional Activity in Biohaven Ltd.
Janus Henderson Group PLC significantly increased its stake in Biohaven, adding 16,127,247 shares to hold a total of 17,534,612 shares valued at about $148.2 million, a 1145.9% increase. BlackRock, Inc. also grew its holdings by 1,774,367 shares, ending with 11,222,407 shares worth approximately $94.9 million, marking an 18.8% increase. Meanwhile, State Street Corp added 902,316 shares, bringing its total to 6,618,803 shares valued at $55.9 million, up by 15.8%.
Insider Buying and Selling at Biohaven Ltd.
Several insiders at Biohaven Ltd. made purchases on April 28, 2026. Notable buyers included Robert Hugin, Irina Antonijevic, John Childs, Gregory Bailey, Julia Gregory, and Michael Thomas Heffernan, each acquiring 68,693 shares. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 29, 2026, B of A Securities downgraded Biohaven Ltd. to a 'sell' with a price target of $11. Previously, on May 13, 2026, Morgan Stanley maintained a 'buy' rating with a target of $18. Citigroup also maintained a 'buy' stance with a $17 target on April 2, 2026. The consensus among analysts remains a 'buy', with an average target price of $22 based on 17 opinions.
About Biohaven Ltd.
Biohaven Ltd. is a biopharmaceutical company headquartered in New Haven, Connecticut. Led by CEO Dr. Vladimir Coric, the company focuses on developing treatments for various conditions in immunology, neuroscience, and oncology. Biohaven is actively engaged in multiple clinical trials, including therapies for Parkinson's disease, focal epilepsy, and rheumatoid arthritis. The company was incorporated in 2022 and employs 274 people.
Bottom Line
Biohaven Ltd. has seen a downgrade from B of A Securities, which may influence investor sentiment. The company remains a subject of interest due to its active development pipeline in the biotech sector. Investors will be watching how these developments impact Biohaven's stock performance, especially given the volatile nature of biotech investments.
Get Biohaven Ltd. alerts
New 13F filings, insider trades, and analyst moves on $BHVN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.